New molecular classifications of breast cancer
- PMID: 19729680
- DOI: 10.3322/caac.20029
New molecular classifications of breast cancer
Abstract
Traditionally, pathologic determinations of tumor size, lymph node status, endocrine receptor status, and human epidermal growth factor receptor 2 (HER2) status have driven prognostic predictions and adjuvant therapy recommendations for patients with early stage breast cancer. However, these prognostic and predictive factors are relatively crude measures, resulting in many patients being overtreated or undertreated. As a result of gene expression assays, there is growing recognition that breast cancer is a molecularly heterogeneous disease. Evidence from gene expression microarrays suggests the presence of multiple molecular subtypes of breast cancer. The recent commercial availability of gene expression profiling techniques that predict risk of disease recurrence as well as potential chemotherapy benefit have shown promise in refining clinical decision making. These techniques will be reviewed in this article.
(c) 2009 American Cancer Society, Inc.
Similar articles
-
Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome.Adv Anat Pathol. 2009 Jul;16(4):204-15. doi: 10.1097/PAP.0b013e3181a9d4bf. Adv Anat Pathol. 2009. PMID: 19546609 Review.
-
Commercialized multigene predictors of clinical outcome for breast cancer.Oncologist. 2008 May;13(5):477-93. doi: 10.1634/theoncologist.2007-0248. Oncologist. 2008. PMID: 18515733 Review.
-
Multiple biomarkers in molecular oncology. II. Molecular diagnostics applications in breast cancer management.Expert Rev Mol Diagn. 2007 May;7(3):269-80. doi: 10.1586/14737159.7.3.269. Expert Rev Mol Diagn. 2007. PMID: 17489734 Review.
-
MicroRNA expression and its implications for the diagnosis and therapeutic strategies of breast cancer.Cancer Treat Rev. 2009 Jun;35(4):328-34. doi: 10.1016/j.ctrv.2008.12.002. Epub 2009 Jan 25. Cancer Treat Rev. 2009. PMID: 19171434 Review.
-
Methods for gene expression profiling in clinical trials of adjuvant breast cancer therapy.Clin Cancer Res. 2006 Feb 1;12(3 Pt 2):1019s-1023s. doi: 10.1158/1078-0432.CCR-05-2296. Clin Cancer Res. 2006. PMID: 16467119
Cited by
-
Expression of MAGE-A and NY-ESO-1 cancer/testis antigens in medullary breast cancer: retrospective immunohistochemical study.Croat Med J. 2011 Apr 15;52(2):171-7. doi: 10.3325/cmj.2011.52.171. Croat Med J. 2011. PMID: 21495200 Free PMC article.
-
A mouse mammary tumor virus env-like exogenous sequence is strictly related to progression of human sporadic breast carcinoma.Am J Pathol. 2011 Oct;179(4):2083-90. doi: 10.1016/j.ajpath.2011.06.046. Epub 2011 Aug 18. Am J Pathol. 2011. PMID: 21854742 Free PMC article.
-
Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial).Breast Cancer Res Treat. 2012 Apr;132(3):871-9. doi: 10.1007/s10549-011-1670-4. Epub 2011 Jul 28. Breast Cancer Res Treat. 2012. PMID: 21796368 Free PMC article.
-
Norepinephrine/β2-Adrenergic Receptor Pathway Promotes the Cell Proliferation and Nerve Growth Factor Production in Triple-Negative Breast Cancer.J Breast Cancer. 2023 Jun;26(3):268-285. doi: 10.4048/jbc.2023.26.e25. J Breast Cancer. 2023. PMID: 37387350 Free PMC article.
-
Candidate tumor suppressor gene IRF6 is involved in human breast cancer pathogenesis via modulating PI3K-regulatory subunit PIK3R2 expression.Cancer Manag Res. 2019 Jun 21;11:5557-5572. doi: 10.2147/CMAR.S203060. eCollection 2019. Cancer Manag Res. 2019. PMID: 31417306 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
